Every material Form 8-K PROCEPT BioRobotics Corp has filed with the SEC since September 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, up 18% from a year earlier, with U.S. procedures up about 22%. The net loss widened to $26.5 million from $21.4 million as operating expenses rose to $92.5 million, and the company reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million. Shareholders see faster sales growth alongside a larger loss.
Revenue of $98.3 million, up 18% from $83.3 million in the third quarter of 2025; U.S. procedures exceeded 13,400, up about 22%
Net loss of $26.5 million, or $0.46 per share, versus a net loss of $21.4 million, or $0.38 per share, a year earlier
Adjusted EBITDA loss of $9.8 million versus $7.4 million; operating expenses rose to $92.5 million from $77.2 million
Full-year 2026 revenue guidance of $390 million to $410 million reiterated; cash and restricted cash totaled $221.4 million as of September 30, 2026
PROCEPT BioRobotics increased its board from nine to ten members and appointed Dr. Michael Mack, a cardiac surgeon, as a director effective immediately. The Board determined Mack is independent under SEC and Nasdaq rules, which adds an independent director with extensive thoracic surgery and medical society leadership experience.
Dr. Michael Mack appointed as Class II director; term expires at the 2029 annual meeting
Board size increased from nine members to ten effective October 2, 2026
Board determined Mack is independent under SEC and Nasdaq rules
Mack will receive non-employee director compensation and sign the Company's standard indemnification agreement
PROCEPT BioRobotics signed a Third Amendment to its loan agreement with Canadian Imperial Bank of Commerce on September 23, 2026, pushing the term loan maturity out by one year. The filing describes this as an administrative extension with no other changes to the loan's covenants, so it matters to shareholders mainly as a change in the timing of debt repayment.
Term Loan Maturity Date extended by 12 months, from October 1, 2027 to October 1, 2028.
Third Amendment dated September 23, 2026, amends a loan agreement originally dated October 6, 2022.
Other terms, including affirmative and negative covenants, remain unchanged according to the filing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PROCEPT BioRobotics Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →